{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bimatoprost+0.01%25+Ophthalmic+Solution",
    "query": {
      "intervention": "Bimatoprost 0.01% Ophthalmic Solution"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bimatoprost+0.01%25+Ophthalmic+Solution&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T11:40:05.468Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02448043",
      "title": "Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nail Growth Cessation",
        "Intraocular Pressure"
      ],
      "interventions": [
        {
          "name": "Bimatoprost 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Placebo: saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2015-06-04",
      "completion_date": "2016-05-06",
      "has_results": true,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 1,
      "location_summary": "Glenview, Illinois",
      "locations": [
        {
          "city": "Glenview",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02448043"
    },
    {
      "nct_id": "NCT01927406",
      "title": "The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroid Eye Disease",
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Prostaglandin Analog",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-06",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2018-05-15",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01927406"
    },
    {
      "nct_id": "NCT00652496",
      "title": "Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Bimatoprost 0.01% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.015% formulation 1 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.015% formulation 2 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.02% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.03% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 249,
      "start_date": "2005-01",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 1,
      "location_summary": "Wenatchee, Washington",
      "locations": [
        {
          "city": "Wenatchee",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00652496"
    },
    {
      "nct_id": "NCT02419508",
      "title": "SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Brinz/brim vehicle",
          "type": "DRUG"
        },
        {
          "name": "Prostaglandin analogue",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2015-08-07",
      "completion_date": "2018-02-27",
      "has_results": true,
      "last_update_posted_date": "2018-11-15",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419508"
    },
    {
      "nct_id": "NCT01253902",
      "title": "Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost ophthalmic solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "travoprost ophthalmic solution 0.004%",
          "type": "DRUG"
        },
        {
          "name": "latanoprost ophthalmic solution 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2010-12",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-07",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 1,
      "location_summary": "Rogers, Arkansas",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253902"
    },
    {
      "nct_id": "NCT05729594",
      "title": "Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Bimatoprost Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-02-27",
      "completion_date": "2023-04-05",
      "has_results": false,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05729594"
    },
    {
      "nct_id": "NCT04890106",
      "title": "Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "Test - Bimatoprost 0.01% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mankind Pharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2021-10-02",
      "completion_date": "2022-08-11",
      "has_results": false,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 9,
      "location_summary": "Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04890106"
    },
    {
      "nct_id": "NCT05401357",
      "title": "Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Test - Bimatoprost 0.01% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amneal Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2022-06-29",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-08-10",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 9,
      "location_summary": "Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "New Smyrna Beach",
          "state": "Florida"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05401357"
    },
    {
      "nct_id": "NCT05397600",
      "title": "Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Bimatoprost Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 684,
      "start_date": "2022-06-22",
      "completion_date": "2024-03-07",
      "has_results": false,
      "last_update_posted_date": "2024-07-18",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 56,
      "location_summary": "Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397600"
    },
    {
      "nct_id": "NCT01863953",
      "title": "A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Fixed-Combination Bimatoprost/Brimonidine",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost Ophthalmic Solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate Ophthalmic Solution 0.2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2013-06",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-10-01T11:40:05.468Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01863953"
    }
  ]
}